At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 36 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 323
- Started
- 2024-03-19
- Last checked
- 2024-05
Plain English Summary
What is this study?
- • Testing a new treatment for infections, bacterial
- • Clinical study - 323 participants
- • The primary aim of the study is to determine the proportion of individuals receiving beta-lactam antibiotics at Imperial College Healthcare NHS Trust in whom drug concentration targets are achieved
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with infections, bacterial
Where?
- • London - Imperial College Healthcare NHS Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The primary aim of the study is to determine the proportion of individuals receiving beta-lactam antibiotics at Imperial College Healthcare NHS Trust in whom drug concentration targets are achieved.
More detail
To address the challenge of antimicrobial resistance (AMR) it is imperative that the current finite pool of antimicrobial agents is optimised, to maximise therapeutic success, limit the risk of drug toxicity, whilst minimising emergence of resistance. Outside of the critical care setting it is not known how many patients are receiving optimal drug concentrations for the treatment of infection. This study aims to assess whether antimicrobial targets are being achieved in these individuals and explore how clinical co-variates and outcomes may relate to this. Furthermore, it aims to identify priority groups and/or drugs where there are gaps in dose optimisation research and develop hypotheses which can be tested in observational studies. Eligible participants will be enrolled and observed during their management of infection at Imperial College NHS Trust. After providing informed consent their clinical data will be collected from electronic healthcare records and they will provide samples that will undergo drug concentration analysis.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓18 years of age or above.
- ✓Under follow-up for management of infection at Imperial College NHS Trust
- ✓Received a beta-lactam antibiotic within the last 48 hours (or are planned to start imminently).
- ✓Provides informed written consent see below, or lacks capacity to provide consent because of one of the following...
- ✓Delirium which may be caused or exacerbated by having an infection.
Who cannot take part
- ✗Less than 18 years of age
- ✗Severe anaemia (Hb \< 70g/l)
- ✗Platelets \< 50x10\^9/l, INR \>1.5 or other known blood clotting impairment
- ✗Patient with terminal diagnosis receiving palliative care input who may experience distress if approached for this...
- ✗Enrolled in a clinical trial which stipulates exclusion from other studies including observational studies.
See the full criteria
Where Is This Study? (1 UK site)
Imperial College Healthcare NHS Trust
London W12 0HS, United Kingdom
How to Get in Touch
Suzy Williams
Sponsor contactCONTACT
Richard Wilson, MPharm
Sponsor contactCONTACT